KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Change in Receivables (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Change in Receivables data on record, last reported at -$51.9 million in Q4 2025.

  • For Q4 2025, Change in Receivables fell 167.32% year-over-year to -$51.9 million; the TTM value through Dec 2025 reached -$25.5 million, down 204.51%, while the annual FY2025 figure was -$25.5 million, 204.51% down from the prior year.
  • Change in Receivables reached -$51.9 million in Q4 2025 per EBS's latest filing, down from $71.6 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $132.4 million in Q2 2023 and bottomed at -$118.5 million in Q2 2025.
  • Average Change in Receivables over 5 years is -$4.1 million, with a median of -$12.2 million recorded in 2022.
  • Peak YoY movement for Change in Receivables: soared 3410.0% in 2023, then plummeted 480.88% in 2025.
  • A 5-year view of Change in Receivables shows it stood at -$98.5 million in 2021, then soared by 57.46% to -$41.9 million in 2022, then rose by 11.93% to -$36.9 million in 2023, then soared by 308.94% to $77.1 million in 2024, then crashed by 167.32% to -$51.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$51.9 million in Q4 2025, $71.6 million in Q3 2025, and -$118.5 million in Q2 2025.